DoW Vision, Mentored Clinical Research Award | HT942526VRPMCRA

FY26 DoD Vision Research Program (VRP) Mentored Clinical Research Award (MCRA) FAQs

1. What is the FY26 VRP Mentored Clinical Research Award (MCRA)?

The FY26 Department of Defense Vision Research Program (VRP) Mentored Clinical Research Award (MCRA) is a discretionary grant mechanism intended to support patient-oriented clinical research focused on vision injury. It is structured to help develop the next generation of clinician-researchers by pairing a trainee clinician with an experienced mentor who serves as the Principal Investigator (PI).

2. What kind of research does this award support?

This award supports strictly clinical, patient-oriented research related to vision injury. The intent is to fund research that can meaningfully improve real-world vision injury care (for example, diagnosis, treatment, rehabilitation, or care delivery) without being a clinical trial.

3. What is the main goal of the MCRA mechanism?

The central goal is to support clinically focused research on vision injury while building the trainee's capabilities as a clinician-researcher through a structured mentorship model. The mechanism emphasizes trainee-led execution of the proposed project under the guidance of an established clinician or Ph.D. clinical scientist PI.

4. Who is this award designed for?

The MCRA is designed for motivated military or civilian clinicians who are still in training and want to conduct patient-oriented clinical research on vision injury. The program is centered on a mentored relationship where the trainee conducts the work under the supervision of the PI.

5. What roles are required in the application?

Applications must include two central roles:

• Principal Investigator (PI): An established clinician or a Ph.D. clinical scientist who serves as the mentor and leads the overall project.
• Trainee clinician: A clinician in training who will conduct the research under the PI's mentorship.

6. Who can serve as the trainee clinician?

The trainee can be a fellow, resident, junior clinician, or a clinician enrolled in a Ph.D. program. The opportunity notes that the trainee should have enough time remaining in their training program to complete the proposed research activities.

7. Can additional research staff or collaborators be included?

Yes. Supporting personnel can be included as needed, but the core of the mechanism is the PI-mentee pairing and the trainee-led execution of the project.

8. Do projects have to be focused on vision injury?

Yes. The opportunity is focused on patient-oriented research related to vision injury, with the purpose of improving vision injury care.

9. Must the proposed work align with VRP Focus Areas?

Yes. A key requirement is that the proposed research must align with at least one of the FY26 VRP Focus Areas.

10. Where can applicants find the FY26 VRP Focus Areas and additional program materials?

The opportunity directs applicants to the CDMRP VRP FY26 materials (including the pre-announcement) at: https://cdmrp.health.mil/pubs/press/2026/vrppreann.

11. Are preclinical studies allowed under this mechanism?

No. The mechanism cannot be used to fund preclinical studies, including lab-based animal studies or bench research.

12. Are clinical trials allowed under this mechanism?

No. The opportunity states that it cannot be used to run clinical trials.

13. What kinds of study designs are appropriate if clinical trials are not allowed?

The opportunity describes eligible work as non-trial, patient-centered clinical research. Examples mentioned or implied include observational studies, outcomes research, clinical epidemiology, or similar approaches that can influence real-world vision injury diagnosis, treatment, rehabilitation, or care delivery without constituting a clinical trial.

14. Can projects be standalone studies, or do they need to be preliminary data efforts?

Either approach is allowed. Projects can be:

• A standalone clinical study with clear, near-term relevance to patients; or
• An effort to generate early clinical research data that helps position a larger, more comprehensive study later on.

15. How are applications reviewed?

Applications are evaluated in two stages:

1. Scored peer review
2. Programmatic review

16. What criteria are used in the scored peer review?

In scored peer review, the opportunity states reviewers will consider:

• The strength of the research idea and rationale
• The soundness of the research strategy and feasibility
• The likely impact of the work
• The qualifications and roles of the personnel

17. What does the programmatic review evaluate?

The programmatic review considers:

• How well the proposal fits the intent of the MCRA mechanism
• How the work contributes to the overall VRP portfolio
• The proposal's relative impact
• Relevance to military health, consistent with the Department of Defense mission focus

18. What are the human subjects oversight requirements?

A major compliance requirement is human subjects oversight documentation. Applicants must provide documentation of Institutional Review Board (IRB) or Ethics Committee (EC) approval, or an official exemption.

19. When is IRB/EC approval (or exemption) documentation due?

IRB/EC approval or an official exemption must be provided no later than January 1, 2027. If this documentation is not provided by that date, the application will not be considered for funding.

20. Why is the IRB/EC timeline important for applicants?

The opportunity notes that studies involving patient data, patient interaction, or identifiable health information often require substantial lead time for ethics review and approvals, so applicants should plan accordingly to meet the January 1, 2027 documentation deadline.

21. Who is the sponsoring agency and who administers the award?

This is a Department of the Army discretionary grant administered through the U.S. Army Medical Research Acquisition Activity (USAMRAA).

22. What is the funding opportunity number?

The funding opportunity number is HT942526VRPMCRA.

23. What is the CFDA number listed for this opportunity?

The opportunity lists CFDA 12.420 (science and technology and other research and development).

24. What is the eligibility for this opportunity?

Eligibility is listed as unrestricted, meaning the opportunity summary does not specify a narrow applicant category.

25. What is the application deadline?

The original application closing date is September 10, 2026.

26. How many awards are expected?

The posting indicates an expectation of two awards.

27. What is the maximum award amount (award ceiling)?

The award ceiling is not specified in the provided source data.

28. Is the research required to be directly relevant to military health?

Relevance to military health is a factor in programmatic review, reflecting the Department of Defense mission focus. The programmatic review evaluates military health relevance as part of its considerations.

29. Is this opportunity intended to support near-term impact for patients?

Yes. The opportunity emphasizes patient-oriented work with clear, near-term relevance to patients (for standalone clinical studies) or early clinical research data generation that positions a future, more comprehensive study.

30. What is the overall emphasis of the program beyond the research project itself?

Beyond the research outcomes, the mechanism strongly emphasizes mentorship and training by requiring a PI-mentee structure and positioning the clinician trainee to conduct the work and benefit from a mentored clinical research experience.